Oakwood Laboratories L.L.C. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 23

Oakwood Laboratories L.L.C. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Oakwood Laboratories L.L.C. - Product Pipeline Review - H2 2011” provides data on the Oakwood Laboratories L.L.C.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oakwood Laboratories L.L.C.’s corporate website, SEC filings, investor presentations and featured press releases, both from Oakwood Laboratories L.L.C. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oakwood Laboratories L.L.C. - Brief Oakwood Laboratories L.L.C. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oakwood Laboratories L.L.C. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oakwood Laboratories L.L.C. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oakwood Laboratories L.L.C.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oakwood Laboratories L.L.C.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oakwood Laboratories L.L.C. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oakwood Laboratories L.L.C

More Info
									          Oakwood Laboratories L.L.C. – Product Pipeline
                      Review – H2 2011
                                                                                          Reference Code: GMDHC01465CDB

                                                                                                 Publication Date: OCT 2011




Oakwood Laboratories L.L.C. – Product Pipeline Review – H2 2011                             GMDHC01465CDB / Published OCT 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Oakwood Laboratories L.L.C. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 3
Oakwood Laboratories L.L.C. Snapshot ................................................................................................................................................................... 4
      Oakwood Laboratories L.L.C. Overview ............................................................................................................................................................. 4
      Key Information .................................................................................................................................................................................................. 4
      Key Facts ........................................................................................................................................................................................................... 4
Oakwood Laboratories L.L.C. – Research and Development Overview .................................................................................................................... 5
      Key Therapeutic Areas ....................................................................................................................................................................................... 5
Oakwood Laboratories L.L.C. – Pipeline Review ...................................................................................................................................................... 7
      Pipeline Products by Stage of Development ....................................................................................................................................................... 7
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 8
Oakwood Laboratories L.L.C. – Pipeline Products Glance ........................................................................................................................................ 9
      Oakwood Laboratories L.L.C. – Late Stage Pipeline .......................................................................................................................................... 9
            Registration Filed Products/Combination Treatment Modalities.................................................................................................................... 9
      Oakwood Laboratories L.L.C.–Early Stage Pipeline Products ...........................................................................................................................10
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................10
Oakwood Laboratories L.L.C. – Drug Profiles ..........................................................................................................................................................11
      Leuprolide .........................................................................................................................................................................................................11
            Product Description ....................................................................................................................................................................................11
            Mechanism of Action...................................................................................................................................................................................11
            R&D Progress .............................................................................................................................................................................................11
      Leuprolide 30 mg ..............................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      Leuprolide 45 mg ..............................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Octreotide .........................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
Oakwood Laboratories L.L.C. – Pipeline Analysis....................................................................................................................................................15
      Oakwood Laboratories L.L.C. – Pipeline Products by Therapeutic Class...................
								
To top